<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39401933</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7533</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery</Title><ISOAbbreviation>Surg Obes Relat Dis</ISOAbbreviation></Journal><ArticleTitle>A randomized, double-blind, placebo-controlled trial of weight loss using liraglutide 3.0 mg for weight recurrence after Roux-en-Y gastric bypass.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S1550-7289(24)00800-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.soard.2024.08.037</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bariatric surgery, such as Roux-en-Y gastric bypass (RYGB) remains the gold standard for treating obesity. Most people regain weight from postsurgery nadir.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Liraglutide 3.0 mg is approved for weight management. This study will examine the effects on liraglutide 3.0 mg on weight regain post-RYGB.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">University Hospital, United States.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A 56-week, double-blind, placebo-controlled study was conducted in 132 subjects, who achieved ≥25% total body weight loss (TBWL) status-post-RYGB and regained ≥10% TBWL after reaching nadir weight (NW). Subjects 18-120 months post-RYGB were randomized to receive liraglutide 3.0 mg/d (n = 89) or placebo (n = 43) with lifestyle counseling regularly for 56 weeks. The co-primary endpoints were the proportion of subjects losing at least 5%, 10%, and 15% TBWL and achieving weight lower than their NW.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">53.4% of the placebo group and 65% of the liraglutide group completed the trial due to Severe acute respiratory syndrome coronavirus 2 pandemic. The change in %TBWL from baseline to 56-weeks was -8.8 (8.5, -29.2 to 9.7) and 1.1 (3.5, -7.9 to 5.99) in the liraglutide and placebo groups, respectively. 76% and 17% of subjects achieved ≥5% TBWL at 56 weeks in the liraglutide and placebo groups, respectively; 51% and 26.0% of the liraglutide group achieved ≥10% and ≥15% TBWL, respectively. None of the placebo group lost ≥10% TBWL. Twenty-one percent of subjects receiving liraglutide surpassed postoperative NW. No subjects on placebo met this goal. Nonserious adverse events occurred in 41.6% of subjects on liraglutide. Serious adverse events (SAE) occurred less often on liraglutide.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Liraglutide was significantly more effective than placebo in treating weight regain that occurs post-RYGB without increased SAE.</AbstractText><CopyrightInformation>Copyright © 2024 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lofton</LastName><ForeName>Holly F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York; Division of Internal Medicine, NYU Grossman School of Medicine, New York, New York. Electronic address: Holly.Lofton@NYULangone.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranga</LastName><ForeName>Gabrielle</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hold</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fielding</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youn</LastName><ForeName>Heekoung</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gujral</LastName><ForeName>Akash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heffron</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fielding</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Bariatric Surgery, NYU Grossman School of Medicine, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Surg Obes Relat Dis</MedlineTA><NlmUniqueID>101233161</NlmUniqueID><ISSNLinking>1550-7289</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bariatric surgery</Keyword><Keyword MajorTopicYN="N">GLP-1 receptor agonist</Keyword><Keyword MajorTopicYN="N">Liraglutide</Keyword><Keyword MajorTopicYN="N">Roux-en-Y gastric bypass</Keyword><Keyword MajorTopicYN="N">Weight recurrence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>21</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39401933</ArticleId><ArticleId IdType="doi">10.1016/j.soard.2024.08.037</ArticleId><ArticleId IdType="pii">S1550-7289(24)00800-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle>